Primus Pharmaceuticals Recalls Unapproved Limbrel Flavocoxid Capsules Nationwide
Primus Pharmaceuticals is recalling Limbrel (flavocoxid 500 mg) capsules because the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 according to the rubric.
Plain-English summary
Primus Pharmaceuticals, Inc. is recalling Limbrel (flavocoxid 500 mg) capsules, 60-count bottles, prescription only. The product was manufactured by Cornerstone Research and Development. The recall covers 135,277 bottles distributed nationwide in the USA.
The FDA is recalling these products because they were marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). According to the agency, the safety and efficacy of these unapproved drugs have not been established.
Consumers who have Limbrel capsules should stop using them and contact their healthcare provider or pharmacist for guidance. The recall applies to all lots within the expiration date.
The recalled product
- Product
- Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.
- Manufacturer
- Primus Pharmaceuticals, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 135,277
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Primus Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Primus Pharmaceuticals, Inc.
See all →- SevereFDA Recalls Unapproved Limbrel Flavocoxid Capsules Nationwide
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Unapproved Limbrel500 Capsules Marketed Without Approval
FDA (Drugs) · 2018-02-21
- SeverePrimus Pharmaceuticals Recalls Unapproved Limbrel250 Capsules Nationwide
FDA (Drugs) · 2018-02-21
Same hazard · unapproved drug
See all →- CriticalBuy-Herbal Recalls Kian Pee Wan Capsules for Undeclared Drug Ingredients
FDA (Drugs) · 2026-08-19
- SevereMR. 7 Super capsules recalled as Class I over undeclared sildenafil
FDA (Drugs) · 2026-03-11
- SevereMojo Max Fusion capsules recalled as Class I over undeclared drug ingredients
FDA (Drugs) · 2026-03-11
- SevereSilintan herbal pills recalled as Class I for undeclared meloxicam
FDA (Drugs) · 2026-03-11
- SevereAgebox iKids-Growth Day Formula Capsules Recalled Over Undeclared Drug Ingredient
FDA (Drugs) · 2026-03-04
Similar recalls
- SevereFDA Recalls Unapproved Ligandrol Supplements Sold Nationwide and in Brazil
FDA (Drugs) · 2016-06-08
- HighAtomoxetine Prescription Capsules Recalled for Impurity Above FDA Recommended Level
FDA (Drugs) · 2025-02-26
- HighClomipramine 50 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12
- HighAtomoxetine Capsules Nationwide Recall for N-Nitroso Impurity Above FDA Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to Excess N-Nitroso Impurity
FDA (Drugs) · 2025-02-26